Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Wolberg, A.S.; Aleman, M.M.; Leiderman, K.; Machlus, K.R. Procoagulant Activity in Hemostasis and Thrombosis: Virchow’s Triad Revisited. Anesth. Analg. 2012, 114, 275–285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tritschler, T.; Kraaijpoel, N.; Gal, G.L.; Wells, P.S. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA 2018, 320, 1583–1594. [Google Scholar] [CrossRef] [PubMed]
- Wijesurendra, R.S.; Casadei, B. Atrial Fibrillation: Effects beyond the Atrium? Cardiovasc. Res. 2015, 105, 238–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mangrolia, N.; Punjabi, P. The Cessation of Oral Anticoagulation Following Left Atrial Appendage Surgery. Future Cardiol. 2018, 14, 407–415. [Google Scholar] [CrossRef] [PubMed]
- Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; et al. ESC Scientific Document Group. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. Eur. Heart J. 2016, 37, 2893–2962. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barco, S.; Granziera, S.; Coppens, M.; Douxfils, J.; Nijkeuter, M.; Riva, N.; Vanassche, T.; Zhang, G.; Lin, M.; Kamphuisen, P.W.; et al. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thromb. Haemost. 2019, 119, 675–684. [Google Scholar] [CrossRef] [PubMed]
- Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS)The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2020, 41, 543–603. [Google Scholar] [CrossRef] [PubMed]
- Cuker, A.; Burnett, A.; Triller, D.; Crowther, M.; Ansell, J.; Van Cott, E.M.; Wirth, D.; Kaatz, S. Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum. Am. J. Hematol. 2019, 94, 697–709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sterne, J.A.; Bodalia, P.N.; Bryden, P.A.; Davies, P.A.; López-López, J.A.; Okoli, G.N.; Thom, H.H.; Caldwell, D.M.; Dias, S.; Eaton, D.; et al. Oral Anticoagulants for Primary Prevention, Treatment and Secondary Prevention of Venous Thromboembolic Disease, and for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis and Cost-Effectiveness Analysis. Health Technol. Assess. Winch. Engl. 2017, 21, 1–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, A.T.; Berger, S.E.; Milenković, D.; Hill, N.R.; Lister, S. Anticoagulant Selection for Patients with VTE-Evidence from a Systematic Literature Review of Network Meta-Analyses. Pharmacol. Res. 2019, 143, 166–177. [Google Scholar] [CrossRef] [PubMed]
- Maura, G.; Billionnet, C.; Drouin, J.; Weill, A.; Neumann, A.; Pariente, A. Oral Anticoagulation Therapy Use in Patients with Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants: Findings from the French Healthcare Databases, 2011–2016. BMJ Open 2019, 9, e026645. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, C.; Ni Choitir, C.; Clarke, S.; Bennett, K.; Barry, M. Direct Oral Anticoagulants Uptake and an Oral Anticoagulation Paradox. Br. J. Clin. Pharmacol. 2020, 86, 392–397. [Google Scholar] [CrossRef] [PubMed]
- Lowres, N.; Giskes, K.; Hespe, C.; Freedman, B. Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circ. J. 2019, 49, 883–907. [Google Scholar] [CrossRef] [PubMed]
- Wilke, T.; Bauer, S.; Mueller, S.; Kohlmann, T.; Bauersachs, R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient-Patient-Cent. Outcomes Res. 2017, 10, 17–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vesa, Ş.C.; Vlaicu, S.I.; Sabin, O.; Văcăraș, V.; Crișan, S.; Istratoaie, S.; Samantar, F.; Popa, D.E.; Macarie, A.E.; Buzoianu, A.D. Evaluating Physician Adherence to Antithrombotic Recommendations in Patients with Atrial Fibrillation: A Pathway to Better Medical Education. Int. J. Environ. Res. Public. Health 2020, 17, 4008. [Google Scholar] [CrossRef] [PubMed]
- Barben, J.; Menu, D.; Rosay, C.; Vovelle, J.; Mihai, A.M.; Nuss, V.; d’Athis, P.; Putot, A.; Manckoundia, P. The Prescription of Direct Oral Anticoagulants in the Elderly: An Observational Study of 19 798 Ambulatory Subjects. Int. J. Clin. Pract. 2020, 74, e13420. [Google Scholar] [CrossRef] [PubMed]
- Robertson, L.; Kesteven, P.; McCaslin, J.E. Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors for the Treatment of Deep Vein Thrombosis. Cochrane Database Syst. Rev. 2015, 6. [Google Scholar] [CrossRef] [PubMed]
- Țica, O.A.; Țica, O.; Antal, L.; Hatos, A.; Popescu, M.I.; Pantea-Stoian, A.; Bratu, O.G.; Găman, M.A.; Pițuru, S.M.; Diaconu, C.C. Modern oral anticoagulant treatment in patients with atrial fibrillation and heart failure: Insights from the clinical practice. Farmacia 2018, 66, 972–976. [Google Scholar] [CrossRef]
- Kartas, A.; Samaras, A.; Vasdeki, D.; Dividis, G.; Fotos, G.; Paschou, E.; Forozidou, E.; Tsoukra, P.; Kotsi, E.; Goulas, I.; et al. Hospitalization Affects the Anticoagulation Patterns of Patients with Atrial Fibrillation. J. Thromb. Thrombolysis 2019, 48, 225–232. [Google Scholar] [CrossRef] [PubMed]
- Haas, S.; Ageno, W.; Weitz, J.I.; Goldhaber, S.Z.; Turpie, A.G.G.; Goto, S.; Angchaisuksiri, P.; Nielsen, J.D.; Kayani, G.; Zaghdoun, A.; et al. Anticoagulation Therapy Patterns for Acute Treatment of Venous Thromboembolism in GARFIELD-VTE Patients. J. Thromb. Haemost. 2019, 17, 1694–1706. [Google Scholar] [CrossRef] [PubMed]
Variables | AF (n = 569) | DVT (n = 105) | p | |
---|---|---|---|---|
Age (years) | 74.6 ± 9.6 | 65.6 ± 14.7 | <0.001 | |
Gender | Female | 295 (51.8%) | 50 (47.6%) | 0.4 |
Male | 274 (48.2%) | 55 (52.4%) | ||
Ischemic heart disease | 390 (68.5%) | 25 (23.8%) | <0.001 | |
Arterial hypertension | 477 (83.8%) | 70 (66.7%) | <0.001 | |
Diabetes mellitus | 149 (26.4%) | 16 (15.2%) | 0.01 | |
Heart failure | 467 (82.1%) | 28 (26.7%) | <0.001 | |
History of stroke | 97 (17.1%) | 4 (3.8%) | <0.001 | |
Peripheral artery disease | 36 (6.3%) | 1 (1%) | 0.04 | |
Obesity | 136 (23.9%) | 42 (40%) | 0.5 | |
Chronic kidney disease | 134 (23.6%) | 11 (10.5%) | 0.004 | |
DOAC | Dabigatran | 35 (6.15%) | 42 (40%) | <0.001 |
Rivaroxaban | 36 (6.3%) | 8 (7.6%) | ||
Apixaban | 53 (9.3%) | 1 (0.9%) | ||
Acenocoumarol | 445 (78.2%) | 54 (52.4%) |
Variables | VKA (499) | DOAC (175) | p | |
---|---|---|---|---|
Condition requiring OAC | AF | 445 (89.2%) | 124 (70.9%) | <0.001 |
DVT | 54 (10.8%) | 51 (29.1%) | ||
Gender | Female | 260 (52.1%) | 85 (48.6%) | 0.4 |
Male | 239 (47.9%) | 90 (51.4%) | ||
Age (years) | 73.7 ± 10.1 | 71.6 ± 13.3 | 0.06 | |
Ischemic heart disease | 333 (66.7%) | 82 (44.9%) | <0.001 | |
Arterial hypertension | 408 (81.8%) | 139 (79.4%) | 0.5 | |
Diabetes mellitus | 137 (27.7%) | 28 (16%) | 0.003 | |
Heart failure | 381 (76.4%) | 114 (65.1%) | 0.005 | |
History of stroke | 68 (13.7%) | 33 (18.9%) | 0.1 | |
Peripheral artery disease | 30 (6%) | 7 (4%) | 0.4 | |
Obesity | 135 (27.1%) | 43 (24.6%) | 0.5 | |
Chronic kidney disease | 109 (21.8%) | 36 (20.6%) | 0.8 | |
All complications related to OAC | 55 (11%) | 8 (4.6%) | 0.01 | |
Complications | Upper GI bleeding | 22 (4.4%) | 5 (2.9%) | 0.09 |
Hematuria | 12 (2.4%) | 2 (1.1%) | ||
Ecchymosis | 10 (2%) | - | ||
Epistaxis | 11 (2.2%) | 1 (0.6%) |
Variables | B | p | OR | 95%CI for OR | |
---|---|---|---|---|---|
Min | Max | ||||
Age | 0.002 | 0.7 | 1.002 | 0.986 | 1.019 |
Atrial fibrillation | 0.968 | <0.001 | 2.633 | 1.564 | 4.433 |
Ischemic heart disease | 0.532 | 0.008 | 1.702 | 1.149 | 2.521 |
Diabetes mellitus | 0.561 | 0.01 | 1.753 | 1.104 | 2.782 |
Heart failure | −0.078 | 0.7 | 0.925 | 0.581 | 1.472 |
Constant | 0.718 | 0.235 | 2.049 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vesa, Ş.C.; Vlaicu, S.I.; Crișan, S.; Sabin, O.; Saraci, G.; Văcăraș, V.; Popa, D.E.; Pârcălab, P.; Donca, V.I.; Macarie, A.E.; et al. Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation. Healthcare 2020, 8, 404. https://doi.org/10.3390/healthcare8040404
Vesa ŞC, Vlaicu SI, Crișan S, Sabin O, Saraci G, Văcăraș V, Popa DE, Pârcălab P, Donca VI, Macarie AE, et al. Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation. Healthcare. 2020; 8(4):404. https://doi.org/10.3390/healthcare8040404
Chicago/Turabian StyleVesa, Ştefan Cristian, Sonia Irina Vlaicu, Sorin Crișan, Octavia Sabin, George Saraci, Vitalie Văcăraș, Daciana Elena Popa, Paula Pârcălab, Valer Ioan Donca, Antonia Eugenia Macarie, and et al. 2020. "Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation" Healthcare 8, no. 4: 404. https://doi.org/10.3390/healthcare8040404